These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
May 24, 2017Sierra Oncology to Present Innovative Clinical Trial Enhancements Leveraging Chk1 Synthetic Lethality in Two Posters at ASCO Annual Meeting
- Company also to present at Jefferies Healthcare Conference at 2pm ET on June 8th - VANCOUVER, May 24, 2017 /CNW/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company...
May 10, 2017
- Phase 1 monotherapy and combination clinical trials amended to focus on novel genetically-driven, prospective patient selection strategy designed to demonstrate synthetic lethality - VANCOUVER,...
May 9, 2017
- Sierra ends Q1 with $125M to fund current operating plans through approximately mid-2019 - - Amendments to ongoing Phase 1 studies submitted to prospectively enroll patients with...
Apr 3, 2017Sierra Oncology Collaborator ICR Reports Preclinical Synthetic Lethality Data for Chk1 Inhibitor SRA737 at AACR
- Research conducted by Professor Paul Workman supports the use of SRA737 in certain genetically defined tumors and in combination with chemotherapy - VANCOUVER, April 3, 2017 /CNW/ - Sierra...
Mar 2, 2017
Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer,...